Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology

John A. Thompson(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Bryan J. Schneider(University of Michigan), Julie R. Brahmer(Sidney Kimmel Comprehensive Cancer Center), Amaka Achufusi(University of Wisconsin Carbone Cancer Center), Philippe Armand(Dana-Farber Brigham Cancer Center), Meghan Berkenstock(Sidney Kimmel Comprehensive Cancer Center), Shailender Bhatia(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Lihua E. Budde(City Of Hope National Medical Center), Saurin Chokshi(St. Jude Children's Research Hospital), Marianne Davies(Smilow Cancer Hospital), Amro Elshoury, Yaron Gesthalter(UCSF Helen Diller Family Comprehensive Cancer Center), Aparna Hegde(University of Colorado Cancer Center), Michael D. Jain(Moffitt Cancer Center), Benjamin H. Kaffenberger(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Melissa G. Lechner(University of Colorado Cancer Center), Tianhong Li(UC Davis Comprehensive Cancer Center), Alissa Marr(Susan Thompson Buffett Foundation), Suzanne McGettigan(University of Pennsylvania), Jordan P. McPherson(University of Utah), Theresa Medina(University of Colorado Cancer Center), Nisha Mohindra(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Anthony J. Olszanski(Fox Chase Cancer Center), Olalekan O. Oluwole(Breast Cancer Research Foundation), Sandip Pravin Patel(University of California San Diego), Pradnya D. Patil(Cleveland Clinic), Sunil Reddy(Cancer Institute (WIA)), Mabel Ryder, Bianca Santomasso(Memorial Sloan Kettering Cancer Center), Scott Shofer(Cancer Institute (WIA)), Jeffrey A. Sosman(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Yinghong Wang(The University of Texas MD Anderson Cancer Center), Vlad G. Zaha(Southwestern Medical Center), Megan Lyons(National Comprehensive Cancer Network), Mary A. Dwyer(National Comprehensive Cancer Network), Lisa Hang(National Comprehensive Cancer Network)
Journal of the National Comprehensive Cancer Network
April 1, 2022
10.6004/jnccn.2022.0020
Cited by 414Open Access
Full Text

Abstract

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions, consisting of medical and hematologic oncologists with expertise across a wide range of disease sites, and experts from the areas of dermatology, gastroenterology, endocrinology, neurooncology, nephrology, cardio-oncology, ophthalmology, pulmonary medicine, and oncology nursing. The content featured in this issue is an excerpt of the recommendations for managing toxicities related to CAR T-cell therapies and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to immune checkpoint inhibitors, visit NCCN.org.

Related Papers

No related papers found

Powered by citation graph analysis